Subscribe to Newsletter

COVID-19

Discovery & Development COVID-19

Corporate Medicine, Government X-Rays

| Angus Stewart

Pfizer’s trial of a new medicine for COVID-19, produced with support from the US Department of Energy, could improve access to treatment.

Business & Regulation Supply Chain

Building Resilience in the Supply Chain

| Sponsored by Thermo Fisher Scientific

We catch up with Christine Callahan from Thermo Fisher Scientific about how suppliers and customers need to reimagine their business models.

Business & Regulation Supply Chain

Strengthening Supply Chains Post-Pandemic

| Sponsored by Thermo Fisher Scientific

We spoke to Prateek Gadhoke, Global Head of Specialty Care Procurement at Sanofi, to ask what makes a strong supply chain.

Discovery & Development Dosage Forms

Gilead Goes Ferreting

| Angus Stewart

A partnership between Gilead Sciences and Georgia State University has tested a new oral antiviral for COVID-19.

Discovery & Development COVID-19

Pharma Versus Omicron

| Stephanie Vine

How will vaccine and therapeutic makers respond to the new SARS-CoV-2 variant?

Discovery & Development Drug Discovery

The Next Frontier in HIV Prevention

| Maryam Mahdi

Exploring the potential of vaccines for treatment equity.

Business & Regulation COVID-19

R&R for an Anti-COVID Europe

| Angus Stewart

The EMA has given the nod to Ronapreve and Regkirona, two monoclonal antibody treatments for COVID-19.

Manufacture Facilities

Swimming with the mRNA Current

| Bill Jarvis

How RNA is making waves in the industry – and leading to new research projects and increased demand for new manufacturing capacities.

Business & Regulation COVID-19

Astra-Amplifiers

| Angus Stewart

Setting its sights on self-amplifying RNA, AstraZeneca has signed a deal with Imperial College London spinoff VaxEquity.

Manufacture Contract Manufacturing Services

Weathering the Storm Together - Part 1

| Stephanie Vine

The efforts of CDMOs have been absolutely crucial in the pandemic response. We ask five CDMO gurus how they reacted to COVID-19.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register